preceding items and other tax events (see note (h) for details); and
results of discontinued operations.
(c) Reported results in 2007 include $1.2 primarily for charges for the
sale of inventories revalued at the date of acquisition. Reported
results in 2006 include $74.1 of charges for the sale of inventories
revalued at the date of acquisition and $0.3 of accelerated
depreciation on manufacturing assets abandoned due to facility
(d) Reported results in 2007 and 2006 include restructuring and other
costs, net, consisting principally of severance, abandoned facility
and other expenses of real estate consolidation, net of
net gains in 2006 on the sale of product lines and abandoned
facilities. Reported results in 2006 also include $15.2 of charges for
in-process research and development associated with the
(e) Reported results in 2006 include a charge for the acceleration of
equity-based compensation expense due to a change in control.
(f) Reported results in 2006 include $0.9 of cost associated with the
early termination of debt/credit facilities in interest expense.
(g) Reported results in 2007 included an $8.9 loss from an other than
temporary decline in the fair market value of an available-for-sale
investment and a $4.5 currency transaction gain associated with an
intercompany financing transaction.
(h) Reported provision for income taxes includes i) $62.2 and $80.6 of
incremental tax benefit in 2007 and 2006, respectively, for the pre-
tax reconciling items between GAAP and adjusted net
income; and ii) in 2007, $11.1 of incremental tax benefit from
adjusting the company's deferred tax balances as a result of newly
enacted tax rates, primarily in Canada.
|SOURCE Thermo Fisher Scientific Inc.|
Copyright©2008 PR Newswire.
All rights reserved